Cargando…

Impact of telmisartan in modifying vascular risk

Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properti...

Descripción completa

Detalles Bibliográficos
Autores principales: Baguet, Jean-Philippe, Ormezzano, Olivier, Barone-Rochette, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172066/
https://www.ncbi.nlm.nih.gov/pubmed/21949624
_version_ 1782211822970994688
author Baguet, Jean-Philippe
Ormezzano, Olivier
Barone-Rochette, Gilles
author_facet Baguet, Jean-Philippe
Ormezzano, Olivier
Barone-Rochette, Gilles
author_sort Baguet, Jean-Philippe
collection PubMed
description Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properties, it has positive metabolic and vascular effects (partly because of its sustained action). Several large-scale trials have focused on the effect of telmisartan on cardiovascular morbidity and mortality, including comparisons of that with an angiotensin-converting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial).
format Online
Article
Text
id pubmed-3172066
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31720662011-09-26 Impact of telmisartan in modifying vascular risk Baguet, Jean-Philippe Ormezzano, Olivier Barone-Rochette, Gilles Integr Blood Press Control Review Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properties, it has positive metabolic and vascular effects (partly because of its sustained action). Several large-scale trials have focused on the effect of telmisartan on cardiovascular morbidity and mortality, including comparisons of that with an angiotensin-converting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial). Dove Medical Press 2010-06-15 /pmc/articles/PMC3172066/ /pubmed/21949624 Text en © 2010 Baguet et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Baguet, Jean-Philippe
Ormezzano, Olivier
Barone-Rochette, Gilles
Impact of telmisartan in modifying vascular risk
title Impact of telmisartan in modifying vascular risk
title_full Impact of telmisartan in modifying vascular risk
title_fullStr Impact of telmisartan in modifying vascular risk
title_full_unstemmed Impact of telmisartan in modifying vascular risk
title_short Impact of telmisartan in modifying vascular risk
title_sort impact of telmisartan in modifying vascular risk
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172066/
https://www.ncbi.nlm.nih.gov/pubmed/21949624
work_keys_str_mv AT baguetjeanphilippe impactoftelmisartaninmodifyingvascularrisk
AT ormezzanoolivier impactoftelmisartaninmodifyingvascularrisk
AT baronerochettegilles impactoftelmisartaninmodifyingvascularrisk